Maturation of Mucosal Immune Responses and Influence of Maternal Antibodies

Journal of Comparative Pathology

Volumn 137, Issue SUPPL. 1, 2007, Pages

  Jonsdottir I ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

IgA; maternal antibodies; mucosal adjuvant; mucosal immune system; neonate; vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CYTOMEGALOVIRUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; MATERNAL ANTIBODY; PARAINFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; RABIES VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; STREPTOCOCCUS VACCINE; TETANUS TOXOID;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL INFECTION; CLOSTRIDIUM TETANI; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GASTROINTESTINAL MUCOSA; HAEMOPHILUS INFLUENZAE TYPE B; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INNATE IMMUNITY; MOUSE; MUCOSAL IMMUNITY; NEWBORN; NONHUMAN; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RABIES; RABIES VIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA; RNA VIRUS INFECTION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TETANUS; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODY FORMATION; HUMANS; IMMUNE SYSTEM; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNITY, MUCOSAL; INFANT, NEWBORN; MICE; VACCINATION;

ANIMALIA; MUS;

EID: 34250866279     PISSN: 00219975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcpa.2007.04.007     Document Type: Article

References (36)

1. Adarna, B.C. (2004). Immune response to novel pneumococcal conjugates and effects of novel adjuvants. M.Sc. Thesis, Faculty of Medicine, University of Iceland.
2. Bjarnarson S.P., Jakobsen H., Del Giudice G., Trannoy E., Siegrist C.A., and Jonsdottir I. The advantage of mucosal immunisation for polysaccharide-specific memory responses in early life. European Journal of Immunology 35 (2005) 1037-1045
3. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., Elvin L., Ensor K.M., Hackell J., Siber G., Malinoski F., Madore D., Chang I., Kohberger R., Watson W., Austrian R., and Edwards K. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanent Vaccine Study Center Group. Pediatric Infectious Disease Journal 19 (2000) 187-195
4. Brandtzaeg P., and Pabst R. Let's go mucosal: communication on slippery ground. Trends in Immunology 25 (2004) 570-577
5. Brynjolfsson, S.F., Bjarnarson, S.P., Del Giudice, G. and Jonsdottir, I. (2006). Neonatal antibody response and immunological memory induced by meningococcal conjugate is enhanced by LT-K63. Proceedings of the 16th European Congress of Immunology, p. 380.
6. Capozzo A.V., Cuberos L., Levine M.M., and Pasetti M.F. Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers. Infection and Immunity 72 (2004) 4637-4646
7. Cutts, F. T., Zaman, S. M., Enwere, G., Jaffar, S., Levine, O. S., Okoko, J. B., Oluwalana, C., Vaughan, A., Obaro, S. K., Leach, A., McAdam, K. P., Biney, E., Saaka, M., Onwuchekwa, U., Yallop, F., Pierce, N. F., Greenwood, B. M., Adegbola, R. A., Gambian Pneumococcal Vaccine Trial Group. (2005). Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet, 365, 1139-1146. (Erratum in: Lancet (2005). 366, 28).
8. De Magistris M.T. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Advances in Drug Delivery Research 58 (2006) 52-67
9. Debertin A.S., Tschernig T., Tonjes H., Kleemann W.J., Troger H.D., and Pabst R. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clinical and Experimental Immunology 134 (2003) 503-507
10. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., and McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20 (2002) 2431-2438
11. Fukuyama S., Nagatake T., Kim D.Y., Takamura K., Park E.J., Kaisho T., Tanaka N., Kurono Y., and Kiyono H. Cutting edge: uniqueness of lymphoid chemokine requirement for the initiation and maturation of nasopharynx-associated lymphoid tissue organogenesis. Journal of Immunology 177 (2006) 4276-4280
12. Hannesdottir S.G., Ólafsdóttir T.A., Del Giudice G., Trannoy T., and Jonsdottir I. The effects of LT-K63 and CpG on the activation status of dendritic cells and cytokine profiles in newborn mice immunised with a conjugate vaccine. Immunobiology 210 (2005) 386
13. Jakobsen H., and Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria-new potentials for conjugate vaccines?. Scandinavian Journal of Immunology 58 (2003) 119-128
14. Jakobsen H., Bjarnarson S., Del Giudice G., Moreau M., Siegrist C.-A., and Jonsdottir I. Intranasal immunisation with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-labile enterotoxin as adjuvant, rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infection and Immunity 70 (2002) 1443-1452
15. Jakobsen, H., Hannesdottir, S.G., Bjarnarson, S.P., Schulz, D., Trannoy, E. Del Giudice, G. and Jonsdottir, I. (2003). Age-dependent T-cell responses to pneumococcal conjugate vaccines: a weak and Th2-biased response in neonates can be circumvented by the adjuvant LT-K63. Proceedings of the 15th European Immunology Congress, p. 125.
16. Jakobsen H., Hannesdottir S., Bjarnarson S.P., Schulz D., Trannoy E., Siegrist C.-A., and Jonsdottir I. Early life T cell responses to pneumococcal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy. European Journal of Immunology 36 (2006) 287-295
17. Kiyono H., and Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nature Reviews Immunology 4 (2004) 699-710
18. Lambert P.-H., Liu M., and Siegrist C.-A. Can successful vaccines teach us how to induce efficient protective immune responses?. Nature Medicine 11 (2005) S54-S62
19. Mahon B.P. The rational design of vaccine adjuvants for mucosal and neonatal immunisation. Current Medicinal Chemistry 8 (2001) 1057-1075
20. + T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proceedings of the National Academy of Science of the USA 102 (2005) 4848-4855
21. McCluskie M.J., and Krieg A.M. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Current Topics in Microbiology and Immunology 311 (2006) 155-178
22. Olafsdottir, T.A., Hannesdottir, S.G., Del Giudice, G., Trannoy, E. and Jonsdottir, I. (2007). Effects of LT-K63 and CpG2006 on phenotype and function of murine neonatal lymphoid cells. Scandinavian Journal of Immunology, in press.
23. Peset Llopis M.J., Harms G., Hardonk M.J., and Timens W. Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells. Journal of Allergy and Clinical Immunology 97 (1996) 1015-1024
24. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., Mills K.H., Rappuoli R., and Del Giudice G. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19 (2001) 2534-2541
25. Premenko-Lanier M., Hodge G., Rota P., Tamin A., Bellini W., and McChesney M. Maternal antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth. Virology 350 (2006) 429-432
26. Pulendran B., and Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124 (2006) 849-863
27. Richter M.Y., Jakobsen H., Haeuw J.F., Power U.F., and Jonsdottir I. Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice. Infection and Immunity 73 (2005) 956-964
28. Shikina T., Hiroi T., Iwatani K., Jang M.H., Fukuyama S., Tamura M., Kubo T., Ishikawa H., and Kiyono H. IgA class switch occurs in the organised nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. Journal of Immunology 172 (2004) 6259-6264
29. Siegrist C.-A. Neonatal and early life vaccinology. Vaccine 19 (2001) 3331-3346
30. Siegrist C.-A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 21 (2003) 3406-3412
31. Sun K., Johansen F.E., Eckmann L., and Metzger D.W. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. Journal of Immunology 173 (2004) 4576-4581
32. Whitney C.G. Impact of conjugate pneumococcal vaccines. Pediatric Infectious Disease Journal 24 (2005) 729-730
33. Wuorimaa T., and Kayhty H. Current state of pneumococcal vaccines. Scandinavian Journal of Immunology 56 (2002) 111-129
34. Xiang Z., Li Y., Gao G., Wilson J.M., and Ertl H.C. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. Journal of Immunology 171 (2003) 4287-4293
35. Zandvoort A., Lodewijk M.E., de Boer N.K., Dammers P.M., Kroese F.G.M., and Timens W. CD27 expression in the human splenic marginal zone: the infant marginal zone is populated by naive B cells. Tissue Antigens 58 (2001) 234-242
36. Zhang Q., Choo S., and Finn A. Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. Infection and Immunity 70 (2002) 5363-5369